168 related articles for article (PubMed ID: 32586008)
1. ROR1 Is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells.
Ghaderi A; Daneshmanesh AH; Moshfegh A; Kokhaei P; Vågberg J; Schultz J; Olin T; Harrysson S; Smedby KE; Drakos E; Rassidakis GZ; Österborg A; Hojjat-Farsangi M; Mellstedt H
Biomedicines; 2020 Jun; 8(6):. PubMed ID: 32586008
[TBL] [Abstract][Full Text] [Related]
2. A ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells.
Ghaderi A; Zhong W; Okhovat MA; Aschan J; Svensson A; Sander B; Schultz J; Olin T; Österborg A; Hojjat-Farsangi M; Mellstedt H
Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297673
[TBL] [Abstract][Full Text] [Related]
3. A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells.
Ghaderi A; Okhovat MA; Lehto J; De Petris L; Manouchehri Doulabi E; Kokhaei P; Zhong W; Rassidakis GZ; Drakos E; Moshfegh A; Schultz J; Olin T; Österborg A; Mellstedt H; Hojjat-Farsangi M
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111634
[TBL] [Abstract][Full Text] [Related]
4. A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib-resistant ROR1
Ghaderi A; Okhovat MA; Wikanthi LSS; Svensson A; Palma M; Schultz J; Olin T; Österborg A; Mellstedt H; Hojjat-Farsangi M
EJHaem; 2021 Aug; 2(3):498-502. PubMed ID: 35844694
[TBL] [Abstract][Full Text] [Related]
5. ROR1 associates unfavorable prognosis and promotes lymphoma growth in DLBCL by affecting PI3K/Akt/mTOR signaling pathway.
Mao Y; Xu L; Wang J; Zhang L; Hou N; Xu J; Wang L; Yang S; Chen Y; Xiong L; Zhu J; Fan W; Xu J
Biofactors; 2019 May; 45(3):416-426. PubMed ID: 30801854
[TBL] [Abstract][Full Text] [Related]
6. A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib.
Daneshmanesh AH; Hojjat-Farsangi M; Ghaderi A; Moshfegh A; Hansson L; Schultz J; Vågberg J; Byström S; Olsson E; Olin T; Österborg A; Mellstedt H
PLoS One; 2018; 13(6):e0198038. PubMed ID: 29856777
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Receptor Tyrosine Kinase ROR1 by Small Molecules.
Hojjat-Farsangi M; Moshfegh A; Schultz J; Norin M; Olin T; Österborg A; Mellstedt H
Handb Exp Pharmacol; 2021; 269():75-99. PubMed ID: 34490515
[TBL] [Abstract][Full Text] [Related]
8. Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma.
Karvonen H; Chiron D; Niininen W; Ek S; Jerkeman M; Moradi E; Nykter M; Heckman CA; Kallioniemi O; Murumägi A; Ungureanu D
Blood Adv; 2017 Nov; 1(24):2257-2268. PubMed ID: 29296874
[TBL] [Abstract][Full Text] [Related]
9. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.
Karvonen H; Perttilä R; Niininen W; Hautanen V; Barker H; Murumägi A; Heckman CA; Ungureanu D
Oncogene; 2019 Apr; 38(17):3288-3300. PubMed ID: 30631148
[TBL] [Abstract][Full Text] [Related]
10. Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies.
Daneshmanesh AH; Porwit A; Hojjat-Farsangi M; Jeddi-Tehrani M; Tamm KP; Grandér D; Lehmann S; Norin S; Shokri F; Rabbani H; Mellstedt H; Österborg A
Leuk Lymphoma; 2013 Apr; 54(4):843-50. PubMed ID: 22988987
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.
Sasi BK; Martines C; Xerxa E; Porro F; Kalkan H; Fazio R; Turkalj S; Bojnik E; Pyrzynska B; Stachura J; Zerrouqi A; Bobrowicz M; Winiarska M; Priebe V; Bertoni F; Mansouri L; Rosenquist R; Efremov DG
Leukemia; 2019 Oct; 33(10):2416-2428. PubMed ID: 30872780
[TBL] [Abstract][Full Text] [Related]
12. The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.
Kuo HP; Ezell SA; Hsieh S; Schweighofer KJ; Cheung LW; Wu S; Apatira M; Sirisawad M; Eckert K; Liang Y; Hsu J; Chen CT; Beaupre D; Chang BY
Am J Cancer Res; 2016; 6(11):2489-2501. PubMed ID: 27904766
[TBL] [Abstract][Full Text] [Related]
13. Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma.
Jiang L; Sun Y; Wang J; He Q; Chen X; Lan X; Chen J; Dou QP; Shi X; Liu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):453. PubMed ID: 31694672
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study.
Ren L; Li L; Zhang L; Li X; Fu X; Wang X; Wu J; Sun Z; Feng X; Chang Y; Zhou Z; Nan F; Yan J; Kong F; Zhang M
Indian J Hematol Blood Transfus; 2022 Jan; 38(1):42-50. PubMed ID: 35115740
[TBL] [Abstract][Full Text] [Related]
15. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
[No Abstract] [Full Text] [Related]
16. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
[TBL] [Abstract][Full Text] [Related]
17. Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers.
Wang ML; Barrientos JC; Furman RR; Mei M; Barr PM; Choi MY; de Vos S; Kallam A; Patel K; Kipps TJ; Rule S; Flanders K; Jessen KA; Ren H; Riebling PC; Graham P; King L; Thurston AW; Sun M; Schmidt EM; Lannutti BJ; Johnson DM; Miller LL; Spurgeon SE
NEJM Evid; 2022 Jan; 1(1):EVIDoa2100001. PubMed ID: 38319241
[TBL] [Abstract][Full Text] [Related]
18. A combination of BR101801 and venetoclax enhances antitumor effect in DLBCL cells via c-Myc/Bcl-2/Mcl-1 triple targeting.
Jeon B; Lee YJ; Shin J; Choi MJ; Lee CE; Son MK; Park JH; Kim BS; Kim HR; Jung KH; Cha JH; Hong SS
Am J Cancer Res; 2023; 13(2):452-463. PubMed ID: 36895970
[TBL] [Abstract][Full Text] [Related]
19. Combination of the dual PIM/PI3-kinase inhibitor IBL-202 and venetoclax is effective in diffuse large B-cell lymphoma.
Gifford G; Stevenson W; Best G
Leuk Lymphoma; 2020 Dec; 61(13):3165-3176. PubMed ID: 32723130
[TBL] [Abstract][Full Text] [Related]
20. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
